The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...

Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...

Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.44 which represents a slight increase of $0.43 or 1.65% from the prior close of $26.01. The stock opened at $26.01 and touched a low ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.